Compare DexCom, Inc. (DXCM) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard Information Technology Index Fund ETF — how do they compare? DexCom, Inc. trades at $77.66 (market cap $28.06B), while Vanguard Information Technology Index Fund ETF trades at $114.24. Which is the better fit depends on your goals.
| DXCM | VGT | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | — |
52-Week High | $89.53 | $125.77 |
52-Week Low | $54.84 | $83.59 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
VGT trades at $114.1, down 2.57% today but maintains a bullish technical outlook with strong moving average signals. The ETF has demonstrated impressive long-term performance with a 10-year average annual return of 25% and 15% since inception. Recent news highlights continued institutional interest in technology sector exposure, though the fund faces competition from lower-cost alternatives like FTEC.
The outlook remains positive given technology sector momentum and AI-driven growth potential. Key risks include sector concentration, valuation concerns, and expense ratio comparisons with competing funds. Wall Street analysts expect technology to outperform the S&P 500, supporting VGT's position as a core technology holding for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
